PerkinElmer, Inc., a global leader committed to innovating for a healthier world, has introduced two ready-to-use HTRF^® and AlphaLISA^® no-wash assay kits designed to quickly and easily detect and quantify CHO HCP impurities during biopharmaceutical manufacturing. Recombinant therapeutic proteins, such as monoclonal antibodies, some vaccines and other biologics, must be free of residual host cell protein (HCP) impurities to prevent immunogenicity or reduced potency, stability or overall effectiveness of a drug.

PerkinElmer's HTRF and AlphaLISA CHO HCP kits are the first on the market designed for ready-to-use homogeneous, no-wash assays for the detection and quantification of CHO HCP impurities. These off-the-shelf kits are designed to deliver a streamlined workflow, a broader dynamic range and higher sensitivity than traditional multi-step ELISA assays. The kits are also easily automatable and can be miniaturized to a small sample volume, significantly increasing throughput to 384-well plates.